A detailed history of State Of Tennessee, Treasury Department transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, State Of Tennessee, Treasury Department holds 60,275 shares of HALO stock, worth $2.75 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
60,275
Previous 64,728 6.88%
Holding current value
$2.75 Million
Previous $3.39 Million 1.74%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$51.3 - $64.42 $228,438 - $286,862
-4,453 Reduced 6.88%
60,275 $3.45 Million
Q2 2024

Aug 13, 2024

BUY
$37.81 - $52.4 $626,284 - $867,953
16,564 Added 34.39%
64,728 $3.39 Million
Q4 2023

Feb 14, 2024

SELL
$33.32 - $42.1 $757,363 - $956,933
-22,730 Reduced 32.06%
48,164 $1.78 Million
Q2 2023

Aug 15, 2023

SELL
$30.28 - $38.74 $403,632 - $516,404
-13,330 Reduced 15.83%
70,894 $2.56 Million
Q1 2023

May 12, 2023

SELL
$32.86 - $55.7 $1.7 Million - $2.87 Million
-51,588 Reduced 37.98%
84,224 $3.22 Million
Q3 2022

Jan 26, 2023

BUY
$38.53 - $51.78 $377,709 - $507,599
9,803 Added 7.78%
135,812 $5.37 Million
Q2 2022

Aug 15, 2022

BUY
$37.35 - $48.3 $2.24 Million - $2.9 Million
60,000 Added 90.9%
126,009 $5.54 Million
Q1 2022

May 11, 2022

BUY
$31.97 - $41.06 $319,700 - $410,600
10,000 Added 17.85%
66,009 $2.63 Million
Q3 2021

Nov 12, 2021

SELL
$38.47 - $46.42 $214,585 - $258,930
-5,578 Reduced 9.06%
56,009 $2.28 Million
Q2 2021

Aug 11, 2021

SELL
$38.84 - $51.31 $3.11 Million - $4.1 Million
-80,000 Reduced 56.5%
61,587 $2.8 Million
Q1 2021

May 10, 2021

BUY
$39.51 - $51.45 $1.25 Million - $1.63 Million
31,587 Added 28.72%
141,587 $5.9 Million
Q4 2020

Feb 09, 2021

BUY
$25.81 - $43.62 $2.84 Million - $4.8 Million
110,000 New
110,000 $4.7 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.36B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track State Of Tennessee, Treasury Department Portfolio

Follow State Of Tennessee, Treasury Department and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Tennessee, Treasury Department, based on Form 13F filings with the SEC.

News

Stay updated on State Of Tennessee, Treasury Department with notifications on news.